1
|
Panchal A, Panchal J, Jain S, Dwivedi J. A literature review on pulmonary arterial hypertension (PAH). CURRENT RESPIRATORY MEDICINE REVIEWS 2022. [DOI: 10.2174/1573398x18666220217151152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
PAH was first of all reported from German Doctor E. Romberg in 1891, It's usually found throughout the globe, but it is a burden in India and other developing countries. Pulmonary arterial hypertension (PAH) is characterized by a rise in pulmonary arterial pressure and the development of progressive symptoms like reduction in functional ability, shortness of breath and fatigue. The pulmonary arteries move blood from the right side of the heart over the lungs.
Introduction:
Increase pressure in pulmonary arteries known as pulmonary arterial pressure (PAH). The treatment of is require because without it, the right heart to work much harder due to high blood pressure in the lungs, and over time it became reason of heart failure. In this article, we have tried to provide brief information about the prevalence, pathology, classification and different therapies of PAH. Combining medicines from different categories is currently given as quality care and has been revealed to boost outcomes. A small part of the new treatment options has been included.
Collapse
Affiliation(s)
| | - Jigar Panchal
- Department of Chemistry, Banasthali Vidyapith Banasthali-304022,
India
| | - Sonika Jain
- Department of Chemistry, Banasthali Vidyapith Banasthali-304022,
India
| | - Jaya Dwivedi
- Department of Chemistry, Banasthali Vidyapith Banasthali-304022,
India
| |
Collapse
|
2
|
Sun XZ, Hu J, Tian XY, Hong Z. Serum expression of Rho kinase, endothelin-1, and nitric oxide in pediatric patients with congenital heart disease accompanied by pulmonary hypertension. Asian J Surg 2021; 45:514-515. [PMID: 34844829 DOI: 10.1016/j.asjsur.2021.11.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2021] [Accepted: 11/10/2021] [Indexed: 11/27/2022] Open
Affiliation(s)
- Xing-Zhen Sun
- Department of Pediatrics, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, 223300, China
| | - Jian Hu
- Department of Pediatrics, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, 223300, China
| | - Xiang-Yang Tian
- Department of Neurology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, 223300, China.
| | - Ze Hong
- Department of Pediatrics, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, 223300, China
| |
Collapse
|
3
|
Abstract
PURPOSE OF REVIEW Pulmonary hypertension is a deadly disease, the causes of which vary between geographical regions. Eighty four percentage of the world's population lives in majority countries (also called low-income and middle-income countries), yet data on pulmonary hypertension in these settings are proportionally scarce. This article provides a review of pulmonary hypertension in majority countries, focusing in detail on the most common causes in these regions, and highlights contextual challenges faced. RECENT FINDINGS Epidemiological data confirms a complex and overlapping array of causes, with pulmonary hypertension because of conditions such as rheumatic heart disease, HIV, schistosomiasis, chronic lung disease and sickle cell disease. Delayed pulmonary hypertension diagnosis remains a concern and is ascribed to a lack of resources and lack of pulmonary hypertension awareness by health professionals. Pulmonary hypertension diagnosis is frequently considered once signs of right heart failure emerge, while echocardiography and right heart catheterization are unavailable in many settings. Accurate data on the prevalence of pulmonary hypertension in many of these regions are needed and could be achieved by establishing and frequent review of national databases where the incident and prevalent pulmonary hypertension cases are captured. SUMMARY There is urgent need for pulmonary hypertension advocacy among clinicians in the primary, secondary and tertiary healthcare sectors of majority countries, and validated noninvasive diagnostic algorithms are needed. Increased awareness and early diagnosis are likely to improve outcomes of pulmonary hypertension patients in these regions, and potentially stimulate locally relevant research.
Collapse
|
4
|
Guo QX, Zhang MY, Wang JG, Zhou F, Liu YQ, Liu JH. [Pulmonary arterial hypertension caused by graft-related thrombotic microangiopathy after ETP-ALL haplotype hematopoietic stem cell transplantation: a case report and literatures review]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2020; 41:164-166. [PMID: 32135636 PMCID: PMC7357948 DOI: 10.3760/cma.j.issn.0253-2727.2020.02.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Indexed: 01/23/2023]
Affiliation(s)
- Q X Guo
- Department of Hematology, The General Hospital of Northern Theater Command, Shenyang 110016, China
| | | | | | | | | | | |
Collapse
|
5
|
Sun XZ, Li SY, Tian XY, Hong Z, Li JX. Effect of Rho kinase inhibitor fasudil on the expression ET-1 and NO in rats with hypoxic pulmonary hypertension. Clin Hemorheol Microcirc 2019; 71:3-8. [PMID: 29660902 DOI: 10.3233/ch-160232] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Xing-Zhen Sun
- Department of Pediatrics, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
| | - Shu-Yan Li
- Department of Ophthalmology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
| | - Xiang-Yang Tian
- Department of Neurology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
| | - Ze Hong
- Department of Pediatrics, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
| | - Jia-Xin Li
- Department of Pediatrics, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
| |
Collapse
|
6
|
Karauzum K, Karauzum I, Kilic T, Sahin T, Baydemir C, Baris Argun S, Celikyurt U, Bildirici U, Agir A. Bendopnea and Its Clinical Importance in Outpatient Patients with Pulmonary Arterial Hypertension. ACTA CARDIOLOGICA SINICA 2018; 34:518-525. [PMID: 30449993 DOI: 10.6515/acs.201811_34(6).20180528a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Purpose Bendopnea is a recently reported novel symptom in patients with heart failure (HF) defined as shortness of breath when bending forward. It has been demonstrated that bendopnea is associated with advanced symptoms and worse outcomes. The aim of this study was to assess the presence of bendopnea and its clinical importance with regards to functional status, hemodynamic and echocardiographic characteristics in outpatient pulmonary arterial hypertension (PAH) patients. Methods We conducted this prospective observational study of 53 patients who were admitted to our PAH clinic for routine control visits. We determined the presence of bendopnea and analyzed hemodynamic parameters, World Heart Organization (WHO) functional class, transcutaneous oxygen saturation, 6-minute walking distance (6-MWD), N-terminal pro-brain natriuretic peptide (NT-proBNP) and right ventricular (RV) function indicators in patients with and without bendopnea. Results Bendopnea was present 33.9% of the PAH patients. The mean age was higher in the patients with bendopnea than in those without bendopnea, but the difference was not significant (p = 0.201). The patients with bendopnea had a lower 6-MWD and higher NT-proBNP level (p < 0.001), and worse WHO functional class symptoms (p = 0.010). Mean right atrial pressure, pulmonary artery pressure, and pulmonary vascular resistance were higher in the patients with bendopnea. The patients with bendopnea had a more dilated RV end-diastolic diameter and lower tricuspid annular plane systolic excursion value (p < 0.001 and p = 0.001, respectively). Conclusions Bendopnea was associated with worse functional capacity status, hemodynamic characteristics and RV function in our outpatient PAH patients.
Collapse
Affiliation(s)
| | | | | | | | | | - Serap Baris Argun
- Department of Pulmonary Diseases, Medical Faculty, Kocaeli University, Kocaeli, Turkey
| | | | | | | |
Collapse
|
7
|
O'Dell WG, Gormaley AK, Prida DA. Validation of the Gatortail method for accurate sizing of pulmonary vessels from 3D medical images. Med Phys 2017; 44:6314-6328. [PMID: 28905390 DOI: 10.1002/mp.12580] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Revised: 08/29/2017] [Accepted: 09/01/2017] [Indexed: 01/19/2023] Open
Abstract
PURPOSE Detailed characterization of changes in vessel size is crucial for the diagnosis and management of a variety of vascular diseases. Because clinical measurement of vessel size is typically dependent on the radiologist's subjective interpretation of the vessel borders, it is often prone to high inter- and intra-user variability. Automatic methods of vessel sizing have been developed for two-dimensional images but a fully three-dimensional (3D) method suitable for vessel sizing from volumetric X-ray computed tomography (CT) or magnetic resonance imaging has heretofore not been demonstrated and validated robustly. METHODS In this paper, we refined and objectively validated Gatortail, a method that creates a mathematical geometric 3D model of each branch in a vascular tree, simulates the appearance of the virtual vascular tree in a 3D CT image, and uses the similarity of the simulated image to a patient's CT scan to drive the optimization of the model parameters, including vessel size, to match that of the patient. The method was validated with a 2-dimensional virtual tree structure under deformation, and with a realistic 3D-printed vascular phantom in which the diameter of 64 branches were manually measured 3 times each. The phantom was then scanned on a conventional clinical CT imaging system and the images processed with the in-house software to automatically segment and mathematically model the vascular tree, label each branch, and perform the Gatortail optimization of branch size and trajectory. Previously proposed methods of vessel sizing using matched Gaussian filters and tubularity metrics were also tested. The Gatortail method was then demonstrated on the pulmonary arterial tree segmented from a human volunteer's CT scan. RESULTS The standard deviation of the difference between the manually measured and Gatortail-based radii in the 3D physical phantom was 0.074 mm (0.087 in-plane pixel units for image voxels of dimension 0.85 × 0.85 × 1.0 mm) over the 64 branches, representing vessel diameters ranging from 1.2 to 7 mm. The linear regression fit gave a slope of 1.056 and an R2 value of 0.989. These three metrics reflect superior agreement of the radii estimates relative to previously published results over all sizes tested. Sizing via matched Gaussian filters resulted in size underestimates of >33% over all three test vessels, while the tubularity-metric matching exhibited a sizing uncertainty of >50%. In the human chest CT data set, the vessel voxel intensity profiles with and without branch model optimization showed excellent agreement and improvement in the objective measure of image similarity. CONCLUSIONS Gatortail has been demonstrated to be an automated, objective, accurate and robust method for sizing of vessels in 3D non-invasively from chest CT scans. We anticipate that Gatortail, an image-based approach to automatically compute estimates of blood vessel radii and trajectories from 3D medical images, will facilitate future quantitative evaluation of vascular response to disease and environmental insult and improve understanding of the biological mechanisms underlying vascular disease processes.
Collapse
Affiliation(s)
- Walter G O'Dell
- Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, 32601, USA
| | - Anne K Gormaley
- Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, 32601, USA
| | - David A Prida
- Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, 32601, USA
| |
Collapse
|
8
|
Vadlamudi HC, Yalavarthi PR, M V BR, Rasheed A, N T. In vitro characterization studies of self-microemulsified bosentan systems. Drug Dev Ind Pharm 2017; 43:989-995. [PMID: 28121194 DOI: 10.1080/03639045.2017.1287720] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
CONTEXT Bosentan is a poorly soluble drug and pose challenges in designing of drug delivery systems. OBJECTIVE The objective of this study is to enhance the solubility, dissolution and shelf-life of bosentan by formulating it as S-SMEDDS capsules. MATERIALS AND METHODS Solubility of bosentan was tested in various liquid vehicles such as oils (rice bran and sunflower), surfactants (span 20 and tween 80) and co-surfactants (PEG 400 and propylene glycol) and microemulsions were developed. Bosentan was incorporated into appropriate microemulsion systems which were previously identified from pseudo ternary phase diagrams. Bosentan-loaded SMEDDS were evaluated for drug content, drug release, zeta potential, and droplet size. The selected liquid SMEDDS were converted into solid SMEDDS by employing adsorption and melt granulation. Solid SMEDDS were characterized for micromeritics and evaluated for drug content, drug release, and shelf-life. RESULTS Isotropic systems R5, R13, S5, and S13 with submicron droplet size had exhibited 85.45, 94.12, 81.67, and 96.64% drug release, respectively. Solid SMEDDS of MR13 and AS13 formulations with rapid reconstitution ability, exhibited 84.85 and 86.74% of on par drug release. The formulations were physicochemically intact for 1.02 and 1.56 years. DISCUSSION Liquid SMEDDS composed with PEG400 had displayed optimal characters. Solid SMEDDS had high-dissolution profiles than bosentan due to modification in the crystalline structure of drug upon microemulsification. CONCLUSION Thus, solid SMEDDS addressed the solubility, dissolution, and stability issues of bosentan and becomes an alternate for clinical convenience.
Collapse
Affiliation(s)
- Harini Chowdary Vadlamudi
- a Department of Pharmaceutics, Centre for Research Studies , Krishna University , Machilipatnam , India.,b Department of Pharmaceutics , PES College of Pharmacy , Bangalore , India
| | | | | | - Arun Rasheed
- e Department of Chemistry , Al-Shifa College of Pharmacy , Poonthavanam , India
| | - Tejeswari N
- c Division of Pharmaceutics , Sri Padmavathi School of Pharmacy , Tirupati , India
| |
Collapse
|
9
|
Harikrishnan S, Sanjay G, Ashishkumar M, Menon J, Rajesh G, Kumar RK. Pulmonary Hypertension Registry of Kerala (PROKERALA) - Rationale, design and methods. Indian Heart J 2016; 68:709-715. [PMID: 27773412 PMCID: PMC5079135 DOI: 10.1016/j.ihj.2015.12.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Accepted: 12/16/2015] [Indexed: 11/23/2022] Open
Abstract
Background Pulmonary hypertension (PH) is a disease associated with a high morbidity and mortality. There is paucity of data regarding PH from the developing countries including India. Idiopathic pulmonary arterial hypertension is the most important etiological factor in the western world, but PH secondary to rheumatic heart disease, chronic obstructive pulmonary disease and untreated congenital heart disease could well be the predominant causes in developing countries like India. The main objective of the PROKERALA study – Pulmonary hypertension Registry Of Kerala is to collect data regarding the etiology, practice patterns and one-year outcomes of patients diagnosed to have PH. Methods The study is a hospital-based registry in the state of Kerala supported and funded by the Cardiological Society of India, Kerala Chapter. A total of 77 hospitals have agreed to participate in the registry. PH was defined as systolic pulmonary artery pressure derived by echocardiography of more than 50 mmHg (by tricuspid regurgitation jet) or mean PA pressure more than 25 mmHg obtained at cardiac catheterization. A detailed questionnaire is administered which includes the demographic characteristics, risk factors, family history, ECG data, 6 minute walk test distance, chest X ray findings and echocardiographic data. Details of PH specific therapy and one-year follow-up data are collected. From a preliminary survey in the region, we estimated that we will be able to collect 2000 cases over a period of one year.
Collapse
Affiliation(s)
- S Harikrishnan
- Additional Professor, Department of Cardiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum 695011, India.
| | - G Sanjay
- Assistant Professor, SCTIMST, Trivandrum, India
| | - M Ashishkumar
- Consultant Cardiologist, Malabar Institute of Medical Sciences, Calicut, India
| | - Jaideep Menon
- Consultant Cardiologist, Amrita Institute for Medical Sciences, Kochi, India
| | - G Rajesh
- Additional Professor, Medical College, Calicut, India
| | - R Krishna Kumar
- Professor, Amrita Institute of Medical Sciences, Kochi, India
| |
Collapse
|
10
|
Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Am J Cardiol 2013; 111:1A-16A; quiz 17A-19A. [PMID: 23414683 DOI: 10.1016/j.amjcard.2012.12.002] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Pulmonary arterial hypertension (PAH), which is a subset of pulmonary hypertension, is a group of diseases distinguished by vascular remodeling of the small pulmonary arteries with associated elevated pulmonary arterial pressure and right ventricular failure. This progressive and sometimes fatal disease occurs as an idiopathic disease or as a component of other disease states. Estimates of the incidence of PAH have varied from 5 to 52 cases/1 million population. Symptoms begin with shortness of breath with exertion and progress to dyspnea with normal activities and, finally, dyspnea at rest. Untreated patients with PAH have a 1-, 3-, and 5-year survival rate of 68%, 48%, and 34%, respectively. Treated, the survival rates improve to 91% to 97% after 1 year and 84% to 91% after 2 years. The current definition of PAH consists of 3 specific hemodynamic assessments confirmed by right heart catheterization findings. One of several important pathophysiologic mechanisms involved in PAH is pulmonary vascular remodeling, which is caused by endothelial and smooth muscle cell hyperproliferation. This is coincident with overexpression of the vasoconstrictor endothelin-1 and a reduction in the vasodilators nitric oxide and prostacyclin, which further impedes proper vasomotor tone, among other effects. Prostacyclin therapies augment the decreased prostacyclin levels in patients with PAH. The currently approved prostacyclins for the treatment of PAH include epoprostenol, iloprost, and treprostinil. Among the 3 medications, the delivery options include intravenous infusion, subcutaneous infusion, and inhaled formulations. Epoprostenol has been shown to have a positive effect on survival in patients with PAH. All prostacyclins have demonstrated improvements in functional class, exercise tolerance, and hemodynamics in patients with PAH. Intravenously and subcutaneously administered formulations of prostacyclins require continuous infusion pump administration, which presents clinical challenges for both the patient and the care provider. Dosing must be individualized and also presents a clinical challenge. Inhaled formulations seem efficacious in moderately symptomatic patients with PAH and might be appropriate when combined with an oral medication. Combination therapies are commonly used in clinical practice, with the decision to do so based on randomized controlled trial data and case study evidence. The present report provides an overview of PAH, the scientific rationale for treatment with prostacyclin therapy, and the benefits and risks of prostacyclin therapy, both as monotherapy and combined with other medications approved for the treatment of PAH.
Collapse
|
11
|
Pulmonary arterial hypertension in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2012; 19:202-7. [PMID: 22960385 DOI: 10.1016/j.bbmt.2012.08.022] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2012] [Accepted: 08/30/2012] [Indexed: 12/19/2022]
Abstract
Pulmonary arterial hypertension (PAH) is rarely included in the differential diagnosis of cardiorespiratory failure after pediatric hematopoietic stem cell transplant (HSCT) as the clinical presentation is nonspecific and may mimic other etiologies. The pathogenesis of PAH in HSCT is poorly understood and the diagnosis requires a high degree of suspicion. We describe 5 children diagnosed with PAH after allogeneic HSCT. All 5 patients had prolonged clinical signs of transplantation-associated thrombotic microangiopathy (TA-TMA) when they presented with hypoxemic respiratory failure and evidence of PAH. Four of the 5 patients had echocardiographic evidence of PAH, and 1 patient was diagnosed with PAH only on autopsy. PAH was diagnosed a median of 76 days (range, 56-101 days) after a diagnosis of TA-TMA. Despite aggressive medical management, including inhaled nitric oxide, 4 of the 5 patients died. One patient recovered from PAH after 11 months of sildenafil therapy. Three of the 4 deceased patients had an autopsy performed, demonstrating severe pulmonary vascular disease consistent with TA-TMA and severe PAH. We conclude that TA-TMA can be associated with significant pulmonary vascular injury presenting as hypoxemic respiratory failure with PAH after HSCT. Pediatric patients with unexplained hypoxemia after HSCT should be evaluated for both transplantation complications, TA-TMA and PAH, accordingly.
Collapse
|